Anygen Overview

  • Founded
  • 2000

Founded
  • Status
  • Public

  • Employees
  • 112

Employees
  • Stock Symbol
  • 196300

Stock Symbol
  • Share Price
  • $6.77

  • (As of Friday Closing)

Anygen General Information

Description

AnyGen Co Ltd is a bio-venture company. The Company manufactures peptide APIs and new drug development. It offers GMP peptides, Generic peptides, Custom peptides, Catalog peptides and other services.

Contact Information

Website
www.anygen.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Primary Office
  • Gwangju Techno Park Test Production Building
  • Suite 206
  • Gwangju, 61008
  • South Korea
+82 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anygen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.77 $6.49 $6.46 - $26.07 $37.9M 5.6M 16.2K -$0.32

Anygen Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 57,044 74,184 69,945 47,287
Revenue 10,191 8,963 7,213 5,383
EBITDA 1,495 1,943 1,069 (3,000)
Net Income (1,749) (1,475) (2,085) (5,698)
Total Assets 25,599 27,239 28,633 26,531
Total Debt 6,690 6,740 12,992 9,135
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Anygen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Anygen‘s full profile, request access.

Request a free trial

Anygen Patents

Anygen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3121195-A1 Novel exenatide analogue and use thereof Granted 21-Mar-2014 0000000000
EP-3121195-B1 Novel exenatide analogue and use thereof Active 21-Mar-2014 000000000
EP-3121195-A4 Novel exenatide analogue and use thereof Granted 21-Mar-2014 000000000 0
US-20170128541-A1 Novel exenatide analogue and use thereof Granted 21-Mar-2014 000000000 0
US-11103557-B2 Exenatide analogue and use thereof Active 21-Mar-2014 C07K14/605 00
To view Anygen’s complete patent history, request access »

Anygen Executive Team (5)

Name Title Board Seat Contact Info
Jae Il. Kim Ph.D Chief Executive Officer & Board Member
Chang Hwan Kim Executive Managing Director & Board Member
Young Joon Kim Board Member & Director of Research & Development
You’re viewing 3 of 5 executive team members. Get the full list »

Anygen Board Members (5)

Name Representing Role Since
Chang Hwan Kim Anygen Executive Managing Director & Board Member 000 0000
Jae Il. Kim Ph.D Anygen Chief Executive Officer & Board Member 000 0000
Joo-yol Choi Hyundai Venture Investment Corporation Board Member 000 0000
Sam Sik Kim Self Board Member 000 0000
Young Joon Kim Anygen Board Member & Director of Research & Development 000 0000
To view Anygen’s complete board members history, request access »

Anygen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial